GLP-1 Market
LLY $1351.12 ▼ -2.3% NVO $38.87 ▼ -1.4% PFE $27.54 ▼ -1.9% VKTX $25.84 ▼ -1.3% KLRA $11.58 ▼ -1.8% GPCR $17.12 ▼ -1.4% RHHBY $58.99 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Acoramidis (AG10)

Acoramidis (AG10)

Company
Eidos Therapeutics, a BridgeBio company
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 20, 2026

Find a Clinical Trial Near Me

See recruiting studies for Acoramidis (AG10) and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07695701

    Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

    Not yet reported Eidos Therapeutics, a BridgeBio company 150 participants Est. completion 2030-11 9 sites Stand-alone
    Other conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
    View official trial listing →
  • Withdrawn NCT NCT04882735

    Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

    Not yet reported Eidos Therapeutics, a BridgeBio company Est. completion 2026-10
    Other conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
    View official trial listing →
  • Active, not recruiting NCT NCT04988386

    Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

    Not yet reported Eidos Therapeutics, a BridgeBio company 389 participants Est. completion 2028-05-15 72 sites
    Other conditions: Amyloid Cardiomyopathy, Transthyretin-Related
    View official trial listing →
  • Not yet recruiting NCT NCT07116473

    To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

    Not yet reported Eidos Therapeutics, a BridgeBio company 250 participants Est. completion 2037-12
    Other conditions: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Acoramidis (AG10), Acoramidis (AG10) oral tablet

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.